ClinicalTrials.gg
Enrolling by invitationNCT07944638NeoMega-REALUpdated Nov 18, 2026

Real-world Follow-up After Introduction of NeoMega36 Fatty-Acid Supplementation in Extremely Preterm Infants

An observational study in Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD) and Necrotizing Enterocolitis (NEC), sponsored by Göteborg University. Enrolling by invitation at 1 site in Sweden. Open to participants aged Up to 28 Days. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Göteborg University · Observational

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,100
Ages
Up to 28 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Retinopathy of Prematurity with a site in Sweden — 1 open to participants now, 2 under way, none of them phase 3. Retinopathy of Prematurity · Sweden.

Started
2026
the only one that year
Observational
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
2 of 10
Göteborg University

Among the 10 studies in Retinopathy of Prematurity with a site in Sweden, this one is the only one that started in 2026, is one of 2 observational ones, and was the 10th registered.

Retinopathy of Prematurity

170 studies on the registry are indexed under Retinopathy of Prematurity; 28 are open to participants now.

Browse Retinopathy of Prematurity studies →

Open to participants now

1 of the 10 studies in Retinopathy of Prematurity with a site in Sweden is open now.

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: Up to 28 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinopathy of Prematurity with a site in Sweden, or all of them as a file.
02

Study summary

Babies born extremely preterm (before 28 weeks of pregnancy) miss most of the transfer of two long-chain fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA), that normally passes from mother to baby in the last three months of pregnancy. Low levels of these fatty acids after birth have been linked to retinopathy of prematurity (ROP), an eye disease that can threaten vision, and to other complications of prematurity. In a Swedish randomized trial (Mega Donna Mega), an enteral supplement of ARA and DHA reduced severe ROP by about half. A similar supplement, NeoMega36, is now used in routine care in several European neonatal units and is being introduced in Sweden.

This observational study examines whether the introduction of NeoMega36 into routine care is followed by less ROP and fewer other complications of prematurity. It compares infants born at 22+0 to 27+6 weeks of gestation who were cared for before NeoMega36 was introduced at their unit (historical period) with infants cared for after it was introduced (NeoMega period).

The study has two parts:

  • European part: participating neonatal units report aggregated counts (number of infants and number with each outcome, by gestational week and period). No individual-level data leave the hospitals.
  • Swedish part: coded individual-level data are retrieved from the Swedish Neonatal Quality Register (SNQ) and the Swedish national register for ROP (SWEDROP).

The study does not give, assign or change any treatment. NeoMega36 is given as part of routine clinical care according to each unit's own practice. There are no extra examinations, visits or contacts with families.

The main hypothesis is that the proportion of infants with severe ROP is lower in the NeoMega period than in the historical period. Other outcomes are treated ROP, any ROP, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), death before discharge, and the combined outcomes BPD or death and NEC or death. Because this is a before-and-after comparison, differences between the periods may also reflect other changes in care over time, and the results will be interpreted with this in mind.

Read the detailed description

DESIGN NeoMega-REAL is a multicentre observational before-and-after (pre/post-implementation) study with two components that share objectives and outcome definitions but are analysed separately: a European component based on aggregated unit-level data and a Swedish component based on individual-level national register data.

EXPOSURE The exposure is implementation of NeoMega36 (an enteral supplement of arachidonic acid and docosahexaenoic acid in a 2:1 ratio) in routine care at the unit. Each unit defines a Historical period before local implementation (preferably 24 months, ideally about twice the length of the NeoMega period, and not overlapping it) and a NeoMega period starting after local implementation (at least 12 months). The main comparison is between periods, regardless of whether an individual infant received the supplement. Within the NeoMega period, units may report how many eligible infants did and did not receive NeoMega36; these counts describe implementation coverage only and are not used for comparative outcome analyses, because receipt can depend on the infant's clinical condition (for example feeding intolerance or nil per os). For each unit, the implementation date, local eligibility criteria, dose regimen, start and stop criteria, handling of interruptions and common reasons for non-use are recorded.

EUROPEAN COMPONENT (AGGREGATED DATA) Participating European neonatal units that have implemented NeoMega36 complete a standardized datasheet (NeoMega-REAL Datasheet Template v2.0). For each period and each gestational week at birth (22+0 to 22+6 up to 27+0 to 27+6, plus all infants), units report counts of eligible infants, infants screened for ROP, severe ROP, treated ROP, any ROP, BPD at 36 weeks postmenstrual age by Jensen grade, NEC (surgical NEC separately where available), death before discharge, BPD or death, and NEC or death. Units also describe, for each period, the use of human milk fortifiers and preterm formula and whether these contain DHA and/or ARA, other routine lipid or fatty-acid supplements, and major changes in feeding or other clinical protocols between periods. Only aggregated counts are submitted: no individual-level data, dates of birth, identifiers or code keys. Units apply the same local definitions in both periods and report any changes in definitions. Data collection from units runs from June to November 2026.

SWEDISH COMPONENT (REGISTER DATA) All infants born before 28 completed weeks of gestation and cared for at Swedish neonatal units during defined periods before and after national implementation of NeoMega36 (from the third quarter of 2026) are identified through the Swedish Neonatal Quality Register (SNQ), which records neonatal characteristics, NeoMega36 exposure and neonatal morbidity, linked with SWEDROP, the national register for retinopathy of prematurity, which records ROP screening, severity and treatment. Data are coded (pseudonymized) and the register holder keeps the code key. Register data are planned to be retrieved annually for about five years after implementation, with the first extraction planned for the third quarter of 2027. Neurodevelopmental data from routine follow-up programmes may later be analysed as an exploratory outcome. No extra examinations, sampling, visits or contacts with children or guardians take place.

DATA QUALITY The coordinating centre checks plausibility and internal consistency (for example, ROP counts not exceeding the number screened, composite outcomes not lower than their components, NeoMega36 given plus not given approximately equal to the total, and complete, non-overlapping period dates). Discrepancies are resolved through queries to the unit and documented in a query log. Files are version-controlled and stored with restricted access on University of Gothenburg secure storage.

STATISTICAL ANALYSIS European component: a two-stage approach. Within each unit, odds ratios for the NeoMega versus Historical period, adjusted for gestational week, are estimated from the aggregated counts; unit-level estimates are pooled by random-effects meta-analysis, and between-unit heterogeneity is assessed (including the I-squared statistic). As a sensitivity analysis, a binomial mixed-effects model with logit link is fitted to the aggregated data, with gestational week as fixed effect and neonatal unit as random effect. Analyses are performed for all infants and by gestational week where data allow. Further sensitivity analyses, where feasible: restriction to units with comparable period lengths and stable screening criteria; exclusion of gestational weeks or units with sparse counts; and alternative denominators for ROP outcomes (infants screened versus all eligible infants). Secondary outcomes are analysed in the same framework where data completeness and event numbers allow. Unit-level nutrition variables are summarized descriptively and may be used in sensitivity analyses.

Swedish component: outcome frequencies are compared between periods overall and by gestational age, using regression models adjusted for background characteristics and calendar period where data allow. Results may be reported separately from, and interpreted alongside, the European results.

SAMPLE SIZE All eligible infants in the defined periods are included. The European component is expected to include about 200 to 300 infants per period in its first phase. Based on Swedish data, 151 infants per period give 80% power (two-sided alpha 0.05, 1:1) to detect a 50% reduction in severe ROP from an incidence of 27.1% among infants born before 28 weeks of gestation.

TIME PERSPECTIVE (OTHER) The European component is retrospective: units report outcomes for infants already born and cared for during the defined periods. The Swedish component is prospectively defined: the post-implementation cohort accrues after national implementation in 2026, and its data are recorded in routine care and retrieved from national registers.

SAMPLING (NON-PROBABILITY) The participating European units are units that have implemented NeoMega36 and agreed to take part. Within each unit, and nationally in Sweden, all consecutive eligible infants born during the defined periods are included, without individual-level selection.

INTERPRETATION Differences between periods cannot be attributed solely to NeoMega36, since changes in case mix, survival, nutrition and other clinical practice over time may also contribute. The study evaluates outcomes after implementation in routine care; it does not estimate an individual-level causal treatment effect.

ETHICS The study has been approved by the Swedish Ethical Review Authority (Dnr 2026-02384-01). Each participating unit is responsible for any local approvals required to share aggregated routine data.

03

Conditions studied

  • Retinopathy of Prematurity (ROP)
  • Bronchopulmonary Dysplasia (BPD)
  • Necrotizing Enterocolitis (NEC)
  • Extreme Prematurity

Keywords

  • Arachidonic Acid
  • Docosahexaenoic Acids
  • Long-chain polyunsaturated fatty acids
  • Dietary Supplements
  • Enteral Nutrition
  • Infant, Extremely Premature
  • Intensive Care Units, Neonatal
  • Controlled Before-After Studies
  • Registries
  • Real-world evidence
  • NeoMega36
04

Who can participate

Ages eligible
Up to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infants born extremely preterm, at 22+0 to 27+6 weeks of gestation, cared for (1) at European neonatal units that have introduced NeoMega36 into routine care, during defined periods before and after local implementation, and (2) at Swedish neonatal units during defined periods before and after national implementation of NeoMega36, identified through the Swedish Neonatal Quality Register (SNQ) and SWEDROP.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born at 22+0 to 27+6 weeks of gestation.
  • Cared for at a participating European neonatal unit, or at a Swedish neonatal unit, during that unit's defined Historical period (before NeoMega36 implementation) or NeoMega period (after implementation).
  • Swedish component: registered in the Swedish Neonatal Quality Register (SNQ), and in SWEDROP for ROP outcomes.

Exclusion criteria

Exclusion Criteria:

  • No individual-level exclusion criteria.
  • Swedish component: missing register data for the outcomes under study.
  • European component: data from a unit or period are excluded if they cannot be delivered according to the data template or remain incomplete or inconsistent after data checks.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Historical period (before NeoMega36 implementation)

    Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period before NeoMega36 was introduced into routine care at that unit (European units: preferably 24 months, not overlapping the NeoMega period; Sweden: a defined period before national implementation). Infants received standard nutrition according to local practice.

  • NeoMega period (after NeoMega36 implementation)

    Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period after NeoMega36 was introduced into routine care at that unit (European units: at least 12 months; Sweden: from national implementation in 2026). All eligible infants in this period are analysed in this group whether or not they individually received NeoMega36; the numbers given and not given the supplement are reported only to describe uptake.

    Dietary Supplement: Enteral arachidonic acid and docosahexaenoic acid supplement

Interventions

  • Dietary supplementEnteral arachidonic acid and docosahexaenoic acid supplement

    Enteral lipid supplement containing arachidonic acid (ARA) and docosahexaenoic acid (DHA) in a 2:1 ratio (NeoMega36, Neobiomics, Solna, Sweden), given in routine neonatal care according to each unit's local protocol for eligibility, dose, and start and stop criteria. The supplement is not assigned, provided or changed by the study. Exposure is defined at period level as implementation of NeoMega36 in routine care at the unit.

    Also known as: NeoMega36

06

What researchers measure

Primary outcomes

  1. Severe retinopathy of prematurity (ROP)

    Number and proportion of infants with ROP stage 3 or higher and/or treated for ROP (ICROP/ETROP-based routine practice), among infants with a final ROP screening outcome. Compared between the NeoMega and Historical periods as an odds ratio adjusted for gestational week (European component: pooled across units by random-effects meta-analysis; Swedish component: regression analysis of register data). The sample size calculation is based on this outcome.

    Time frame: From birth until completion of ROP screening (final screening outcome), usually by about 40 to 45 weeks postmenstrual age

Secondary outcomes

  1. Treated retinopathy of prematurity (ROP)

    Number and proportion of infants who received ROP treatment (for example anti-VEGF injection and/or laser), regardless of stage or type, according to local practice, among infants with a final ROP screening outcome. Compared between the NeoMega and Historical periods as an odds ratio adjusted for gestational week.

    Time frame: From birth until completion of ROP screening (final screening outcome), usually by about 40 to 45 weeks postmenstrual age

  2. Any retinopathy of prematurity (ROP)

    Number and proportion of infants who developed ROP of any stage, among infants with a final ROP screening outcome. Compared between the NeoMega and Historical periods as an odds ratio adjusted for gestational week.

    Time frame: From birth until completion of ROP screening (final screening outcome), usually by about 40 to 45 weeks postmenstrual age

  3. Bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age, by Jensen grade

    Number and proportion of infants with BPD graded by respiratory support at 36 weeks postmenstrual age (Jensen et al. 2019): no BPD, no support; grade 1, nasal cannula at 2 L/min or less; grade 2, nasal cannula above 2 L/min or non-invasive positive airway pressure; grade 3, invasive mechanical ventilation. Among infants alive at 36 weeks postmenstrual age; compared between the NeoMega and Historical periods.

    Time frame: At 36 weeks postmenstrual age

  4. BPD or death before 36 weeks postmenstrual age (composite)

    Number and proportion of infants with BPD at 36 weeks postmenstrual age or death before BPD assessment, each infant counted once. Compared between the NeoMega and Historical periods.

    Time frame: From birth to 36 weeks postmenstrual age

  5. Necrotizing enterocolitis (NEC)

    Number and proportion of infants with NEC as documented in routine care. Compared between the NeoMega and Historical periods.

    Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age

  6. Surgical necrotizing enterocolitis (NEC)

    Number and proportion of infants with NEC requiring surgery, where reported. Compared between the NeoMega and Historical periods.

    Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age

  7. NEC or death before discharge (composite)

    Number and proportion of infants with NEC or death before discharge, each infant counted once. Compared between the NeoMega and Historical periods.

    Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age

  8. Death before discharge

    Number and proportion of infants who died before discharge from neonatal care. Where available, death before the final ROP screening outcome and death before 36 weeks postmenstrual age are also reported. Compared between the NeoMega and Historical periods.

    Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age

Other outcomes

  1. Uptake of NeoMega36 during the NeoMega period

    Number and proportion of eligible infants who received and did not receive NeoMega36 during the NeoMega period, with aggregated reasons for non-use where available. Descriptive only; not used for comparative outcome analyses.

    Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age

  2. Other neonatal morbidities in the Swedish cohort

    Occurrence of other prematurity-related complications recorded in the Swedish Neonatal Quality Register, such as sepsis and patent ductus arteriosus, compared between the NeoMega and Historical periods.

    Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age

07

Study locations

1 site
  • Sahlgrenska Academy, University of Gothenburg
    Gothenburg, Sweden
08

References and documents

Publications

  • Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019 Sep 15;200(6):751-759. doi: 10.1164/rccm.201812-2348OC. PubMed 30995069 ↗
  • Hellstrom A, Nilsson AK, Wackernagel D, Pivodic A, Vanpee M, Sjobom U, Hellgren G, Hallberg B, Domellof M, Klevebro S, Hellstrom W, Andersson M, Lund AM, Lofqvist C, Elfvin A, Savman K, Hansen-Pupp I, Hard AL, Smith LEH, Ley D. Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr. 2021 Apr 1;175(4):359-367. doi: 10.1001/jamapediatrics.2020.5653. PubMed 33523106 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The European component collects only aggregated unit-level counts, so no individual participant data are held by the investigators. Swedish individual-level data are pseudonymized data released by the national quality registers (SNQ and SWEDROP) for this approved project only; other researchers can apply for these data directly from the register holders, subject to ethical approval. Aggregated results will be published.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2031, 61 months after the start.

Of 26 observational studies under Retinopathy of Prematurity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 18, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Aug 8, 2031
CompletionEst.
Mar 31, 2036
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944638
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jun 16, 2026
Primary completion
Aug 8, 2031 (estimated)
Completion
Mar 31, 2036 (estimated)
Last update
Nov 18, 2026

Study contacts

Anders K Nilsson, PhD
principal investigator · University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion